77 patients completed the study and all patients were positive for nanobacteria serology, antigen or both. Among those patients, 57% had a statistically significant decrease in their CAC score as measured using cardiac computerized tomography, the average decrease being 14% (p=0.001). In addition, 84% of patients with angina, or chest pain, had improvement or total resolution of pain. Many of these patients (86%) were on continuous statin medication before the trial and there was still a marked improvement in their cholesterol and triglyceride levels on comET. Nanobac's NB2, antigen and antibody blood test was used to evaluate the patients nanobacterial levels and all of these cardiac patients were positive for nanobacterial infection. Since CAC scores decreased during the therapy in most patients, the study suggests that the heart arteries have become less clogged while on this proposed anti-nanobacterial therapy. CAC scores are thought to increase by 20% annually. There are no previous reports showing a significant decrease in CAC scores with any regimen found in literature.

"It is quite remarkable to see an improvement in CAC scores and lipid levels in any group of patients, but especially in this group in which many had severe refractory heart disease," said Benedict Maniscalco, MD, FACC, study principal investigator. "The association between calcium and heart disease has been known for some time but we now have a probable link between nanobacteria, calcium and heart disease. This has the potential to change the way cardiologists practice medicine and merits further study in controlled clinical trials to confirm and expand the findings from this observational study."

"Heart disease is the number one killer in America and unfortunately a fatal heart attack is often the first warning sign. That is why much attention has been given to the testing for cardiac risk factors, like cholesterol and Hs-CRP," said John Stanton, Nanobac's CEO. "Our NB2 test may prove to be another tool to help predict a patient's cardiac risk by allowing physicians to conveniently measure a patients CAC score with a simple blood test. Further, continued study of our proprietary nanobiotic regimen could provide a way to measurably improve a patient's cardiac health."

About Nanobacteria

Nanobacterium sanguineum (nanobacteria) is the smallest self-replicating organism ever detected - at 50 to 500 billionths of a meter, 1/1000th the size of the smallest previously known bacteria. Nanobacteria have been implicated in a variety of human diseases associated with pathological calcification.

Nanobacteria were first discovered in 1988 by a Finnish researcher, and Nanobac OY co-Founder Olavi Kajander, M.D., Ph.D. Neva Ciftcioglu, Ph.D. joined his team in 1991 and their corroborated work with nanobacteria over the past 13 years has put them at the forefront of research into this medically important pathogen. Their research established that the blood-borne nanobacteria forms slow-growing calcified colonies in arteries and organs. Dr. Kajander participated in the current study.

Nanobac has identified two biomarkers of nanobacterial infection. These tests are being developed as the NB2 test, which is composed of the nanobacteria antigen test, and the nanobacteria IgG antibody test. The Nanobac IgG test is designed to measure the body's immune response to the nanobacterial infection. The Company is in the final stages of development of the nanobacteria antigen test.

About Coronary Artery Disease

Coronary artery disease (CAD) is the primary cause of death in the United States. More than 5 million people in the United States have coronary artery disease (CAD). When CAD is present, plaque buildup reduces blood flow through the arteries. If left untreated, CAD may result in a myocardial infarction, which is known as a heart attack.

About Nanobac

Nanobac Life Sciences, Inc. is dedicated to improving people's health through the detection and eradication of Nanobacterium sanguineum (nanobacteria). The Company's pioneering research is establishing the pathogenic role of nanobacteria in calcification, particularly in coronary artery heart disease and vascular disease. Nanobac has identified two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assay to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop the first FDA approved therapeutic to detect and treat nanobacterial infection. The Company currently markets, through its wholly owned subsidiary, Nanobac Sciences, a patented nanobiotic regimen that it developed.

Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobaclifesciences.com/.